0.5 mg retatrutide Promises Big Weight Loss, but Safety Remains a Question image.cfm?name=7.5mg+(3).jpg&id=907721

GLP-1 weight loss drugs gain popularity among insured employees, raising employer costs and prompting coverage reconsiderations to manage budgets effectively.

Implications GLP-1RAs represent a novel, multifaceted therapeutic option in PsD, targeting both metabolic and inflammatory components

Supports gut barrier strength and digestive balance

Eli Lilly quietly cancelled a clinical trial for an experimental drug to slow muscle loss in obesity patients taking its GLP-1 weight loss drug

FDA Approves Oral Semaglutide as a GLP-1 Pill for Weight Loss at Centra Internal Medicine

Companies pitching 'AI-powered nutrition' as a generic chatbot have the wrong product